Association of Systemic Sclerosis and Periodontitis with Vitamin D Levels
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Population
2.3. Data Collection
2.4. Laboratory Analyses
2.5. Power Sample Size
2.6. Statistical Analysis
3. Results
3.1. Patient Population
3.2. Primary Outcome
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bellando-Randone, S.; Matucci-Cerinic, M. Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions. Curr. Rheumatol. Rep. 2017, 19, 65. [Google Scholar] [CrossRef]
- Gueiros, L.A.; France, K.; Posey, R.; Mays, J.W.; Carey, B.; Sollecito, T.P.; Setterfield, J.; Bin Woo, S.; Culton, D.; Payne, A.S.; et al. World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren’s syndrome: A systematic review. Oral Dis. 2019, 25, 102–110. [Google Scholar] [CrossRef] [Green Version]
- Matucci-Cerinic, M.; Kahaleh, B.; Wigley, F.M. Review: Evidence That Systemic Sclerosis Is a Vascular Disease. Arthritis Rheum. 2013, 65, 1953–1962. [Google Scholar] [CrossRef] [PubMed]
- Man, A.; Zhu, Y.; Zhang, Y.; Dubreuil, M.; Rho, Y.H.; Peloquin, C.; Simms, R.W.; Choi, H.K. The risk of cardiovascular disease in systemic sclerosis: A population-based cohort study. Ann. Rheum. Dis. 2012, 72, 1188–1193. [Google Scholar] [CrossRef] [PubMed]
- Meier, C.; Freiburghaus, K.; Bovet, C.; Schniering, J.; Allanore, Y.; Distler, O.; Nakas, C.; Maurer, B. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease. Sci. Rep. 2020, 10, 21912. [Google Scholar] [CrossRef]
- Tonetti, M.S.; Greenwell, H.; Kornman, K.S. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J. Periodontol. 2018, 89, S159–S172. [Google Scholar] [CrossRef] [Green Version]
- Isola, G.; Polizzi, A.; Alibrandi, A.; Williams, R.C.; Leonardi, R. Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels. J. Periodontol. 2020. [CrossRef]
- Zeidán-Chuliá, F.; Yilmaz, D.; Häkkinen, L.; Könönen, E.; De Oliveira, B.-H.N.; Güncü, G.; Uitto, V.-J.; Caglayan, F.; Gürsoy, U.K. Matrix metalloproteinase-7 in periodontitis with type 2 diabetes mellitus. J. Periodontal Res. 2018, 53, 916–923. [Google Scholar] [CrossRef]
- Kim, O.S.; Shin, M.H.; Kweon, S.S.; Lee, Y.H.; Kim, O.J.; Kim, Y.J.; Chung, H.J. The severity of periodontitis and metabolic syndrome in Korean population: The Dong-gu study. J. Periodontal Res. 2017, 53, 362–368. [Google Scholar] [CrossRef]
- Isola, G.; Williams, R.C.; Gullo, A.L.; Ramaglia, L.; Matarese, M.; Iorio-Siciliano, V.; Cosio, C.; Matarese, G. Risk association between scleroderma disease characteristics, periodontitis, and tooth loss. Clin. Rheumatol. 2017, 36, 2733–2741. [Google Scholar] [CrossRef] [PubMed]
- Da Silva, G.S.G.; De Melo, M.L.M.; Leão, J.C.; Carvalho, A.T.; Porter, S.; Duarte, A.L.B.P.; Dantas, A.T.; Gueiros, L.A. Oral features of systemic sclerosis: A case–control study. Oral Dis. 2019, 25, 1995–2002. [Google Scholar] [CrossRef]
- Holick, M.F. The vitamin D deficiency pandemic and consequences for nonskeletal health: Mechanisms of action. Mol. Asp. Med. 2008, 29, 361–368. [Google Scholar] [CrossRef] [Green Version]
- Cabras, M.; Gambino, A.; Broccoletti, R.; Lodi, G.; Arduino, P.G. Treatment of angular cheilitis: A narrative review and authors’ clinical experience. Oral Dis. 2019, 26, 1107–1115. [Google Scholar] [CrossRef]
- Hewison, M. An update on vitamin D and human immunity. Clin. Endocrinol. 2012, 76, 315–325. [Google Scholar] [CrossRef]
- Jamali, N.; Sorenson, C.M.; Sheibani, N. Vitamin D and regulation of vascular cell function. Am. J. Physiol. Circ. Physiol. 2018, 314, H753–H765. [Google Scholar] [CrossRef] [Green Version]
- Al Hamad, A.; Lodi, G.; Porter, S.; Fedele, S.; Mercadante, V. Interventions for dry mouth and hyposalivation in Sjögren’s syndrome: A systematic review and meta-analysis. Oral Dis. 2018, 25, 1027–1047. [Google Scholar] [CrossRef]
- Rosen, Y.; Daich, J.; Soliman, I.; Brathwaite, E.; Shoenfeld, Y. Vitamin D and autoimmunity. Scand. J. Rheumatol. 2016, 45, 439–447. [Google Scholar] [CrossRef]
- Bi, C.S.; Wang, J.; Qu, H.L.; Li, X.; Tian, B.M.; Ge, S.; Chen, F.M. Calcitriol suppresses lipopolysaccharide-induced alveolar bone damage in rats by regulating T helper cell subset polarization. J. Periodontal Res. 2019, 54, 612–623. [Google Scholar] [CrossRef]
- Gong, A.; Chen, J.; Wu, J.; Li, J.; Wang, L.; Goltzman, D.; Miao, D. 1,25-dihydroxyvitamin D deficiency accelerates alveolar bone loss independent of aging and extracellular calcium and phosphorus. J. Periodontol. 2018, 89, 983–994. [Google Scholar] [CrossRef]
- Isola, G.; Alibrandi, A.; Rapisarda, E.; Matarese, G.; Williams, R.C.; Leonardi, R. Association of vitamin D in patients with periodontitis: A cross-sectional study. J. Periodontal Res. 2020, 55, 602–612. [Google Scholar] [CrossRef]
- Hu, X.; Niu, L.; Ma, C.; Huang, Y.; Yang, X.; Shi, Y.; Pan, C.; Liu, J.; Wang, H.; Li, Q.; et al. Calcitriol decreases live Porphyromonas gingivalis internalized into epithelial cells and monocytes by promoting autophagy. J. Periodontol. 2019, 91, 956–966. [Google Scholar] [CrossRef]
- Millen, A.E.; Hovey, K.M.; LaMonte, M.J.; Swanson, M.; Andrews, C.A.; Kluczynski, M.A.; Genco, R.J.; Wactawski-Wende, J. Plasma 25-Hydroxyvitamin D Concentrations and Periodontal Disease in Postmenopausal Women. J. Periodontol. 2013, 84, 1243–1256. [Google Scholar] [CrossRef] [Green Version]
- Dietrich, T.; Nunn, M.; Dawson-Hughes, B.; Bischoff-Ferrari, H.A. Association between serum concentrations of 25-hydroxyvitamin D and gingival inflammation. Am. J. Clin. Nutr. 2005, 82, 575–580. [Google Scholar] [CrossRef] [PubMed]
- Isola, G.; Lo Giudice, A.; Polizzi, A.; Alibrandi, A.; Murabito, P.; Indelicato, F. Identification of the different salivary Interleukin-6 profiles in patients with periodontitis: A cross-sectional study. Arch. Oral Biol. 2021, 122, 104997. [Google Scholar] [CrossRef] [PubMed]
- Masi, A.T. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23, 581–590. [Google Scholar] [CrossRef]
- White, B.; Bauer, E.A.; Goldsmith, L.A.; Hochberg, M.C.; Katz, L.M.; Korn, J.H.; Lachenbruch, P.A.; LeRoy, E.C.; Mitrane, M.P.; Paulus, H.E.; et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum. 1995, 38, 351–360. [Google Scholar] [CrossRef] [PubMed]
- Isola, G.; Polizzi, A.; Patini, R.; Ferlito, S.; Alibrandi, A.; Palazzo, G. Association among serum and salivary A. actinomycetemcomitans specific immunoglobulin antibodies and periodontitis. BMC Oral Health 2020, 20, 283. [Google Scholar] [CrossRef] [PubMed]
- Antonoglou, G.N.; Suominen, A.L.; Knuuttila, M.; Ylöstalo, P.; Ojala, M.; Männistö, S.; Marniemi, J.; Lundqvist, A.; Tervonen, T. Associations Between Serum 25-Hydroxyvitamin D and Periodontal Pocketing and Gingival Bleeding: Results of a Study in a Non-Smoking Population in Finland. J. Periodontol. 2015, 86, 755–765. [Google Scholar] [CrossRef] [PubMed]
- Männistö, S.; Virtanen, M.; Mikkonen, T.; Pietinen, P. Reproducibility and validity of a food frequency questionnaire in a case-control study on breast cancer. J. Clin. Epidemiol. 1996, 49, 401–409. [Google Scholar] [CrossRef]
- Furst, D.E.; Clements, P.J.; Steen, V.D.; Medsger, T.A., Jr.; Masi, A.T.; D’Angelo, W.A.; Lachenbruch, P.A.; Grau, R.G.; Seibold, J.R. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J. Rheumatol. 1998, 25, 84–88. [Google Scholar]
- O’Leary, T.J.; Drake, R.B.; Naylor, J.E. The Plaque Control Record. J. Periodontol. 1972, 43, 38. [Google Scholar] [CrossRef] [PubMed]
- Polizzi, A.; Santonocito, S.; Di Stefano, M.; Ferlito, S.; Indelicato, F.; Palazzo, G. The effects on oral related quality of life induced by periodontitis in patients with juvenile idiopathic arthritis. Mediterr. J. Clin. Psychol. 2020, 8, 1. [Google Scholar] [CrossRef]
- Zhang, L.; Duan, Y.; Zhang, T.P.; Huang, X.L.; Li, B.Z.; Ye, D.Q.; Wang, J. Association between the serum level of vitamin D and systemic sclerosis in a Chinese population: A case control study. Int. J. Rheum. Dis. 2017, 20, 1002–1008. [Google Scholar] [CrossRef]
- Ketharanathan, V.; Torgersen, G.R.; Petrovski, B.É.; Preus, H.R. Radiographic alveolar bone level and levels of serum 25-OH-Vitamin D3 in ethnic Norwegian and Tamil periodontitis patients and their periodontally healthy controls. BMC Oral Heal. 2019, 19, 1–7. [Google Scholar] [CrossRef]
- Arnson, Y.; Amital, H.; Agmon-Levin, N.; Alon, D.; Sánchez-Castañón, M.; López-Hoyos, M.; Matucci-Cerinic, M.; Szucs, G.; Shapira, Y.; Szekanecz, Z.; et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: A retrospective cohort study and review of the literature. Autoimmun. Rev. 2011, 10, 490–494. [Google Scholar] [CrossRef]
- Lo Gullo, A.; Mandraffino, G.; Sardo, M.A.; D’Ascola, A.; Mamone, F.; Loddo, S.; Alibrandi, A.; Imbalzano, E.; Mormina, E.; Saitta, C.; et al. Circulating progenitor cells in rheumatoid arthritis: Association with inflammation and oxidative stress. Scand. J. Rheumatol. 2013, 43, 184–193. [Google Scholar] [CrossRef]
- Lo Gullo, A.; Mandraffino, G.; Bagnato, G.; Aragona, C.O.; Imbalzano, E.; D’Ascola, A.; Rotondo, F.; Cinquegrani, A.; Mormina, E.; Saitta, C.; et al. Vitamin D Status in Rheumatoid Arthritis: Inflammation, Arterial Stiffness and Circulating Progenitor Cell Number. PLoS ONE 2015, 10, e0134602. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zerr, P.; Vollath, S.; Palumbo-Zerr, K.; Tomcik, M.; Huang, J.; Distler, A.; Beyer, C.; Dees, C.; Gela, K.; Distler, O.; et al. Vitamin D receptor regulates TGF-β signalling in systemic sclerosis. Ann. Rheum. Dis. 2015, 74, e20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Santonocito, S.; Ronsivalle, V.; Fichera, G.; Indelicato, F. Psychological impact and patient perception of occlusion and orthodontic treatment in periodontitis patients. Mediterr. J. Clin. Psychol. 2020, 8. [Google Scholar] [CrossRef]
- Taylan, A.; Birlik, M.; Kenar, G.; Toprak, B.; Gundogdu, B.; Gurler, O.; Karakas, B.; Akıncı, B.; Sisman, A.R. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors. Mod. Rheumatol. 2019, 29, 619–624. [Google Scholar] [CrossRef]
- Yang, C.-Y.; Leung, P.S.C.; Adamopoulos, I.E.; Gershwin, M.E. The Implication of Vitamin D and Autoimmunity: A Comprehensive Review. Clin. Rev. Allergy Immunol. 2013, 45, 217–226. [Google Scholar] [CrossRef] [PubMed]
- Meghil, M.M.; Hutchens, L.; Raed, A.; Multani, N.A.; Rajendran, M.; Zhu, H.; Looney, S.; Elashiry, M.; Arce, R.M.; Peacock, M.E.; et al. The influence of vitamin D supplementation on local and systemic inflammatory markers in periodontitis patients: A pilot study. Oral Dis. 2019, 25, 1403–1413. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.-C.; Ninomiya, T.; Hosoya, A.; Hiraga, T.; Miyazawa, H.; Nakamura, H. 1α,25-Dihydroxyvitamin D3 inhibits osteoblastic differentiation of mouse periodontal fibroblasts. Arch. Oral Biol. 2012, 57, 453–459. [Google Scholar] [CrossRef] [PubMed]
- Agrawal, D.K.; Yin, K. Vitamin D and inflammatory diseases. J. Inflamm. Res. 2014, 7, 69–87. [Google Scholar] [CrossRef] [Green Version]
- Hiremath, V.P.; Rao, C.B.; Naik, V.; Prasad, K.V. Anti-inflammatory effect of vitamin D on gingivitis: A dose-response randomised control trial. Oral Health Prev. Dent. 2013, 11, 61–69. [Google Scholar] [CrossRef] [PubMed]
- Grenier, D.; Morin, M.; Fournier-Larente, J.; Chen, H. Vitamin D inhibits the growth of and virulence factor gene expression by Porphyromonas gingivalis and blocks activation of the nuclear factor kappa B transcription factor in monocytes. J. Periodontal Res. 2016, 51, 359–365. [Google Scholar] [CrossRef]
- Lai, H.; Fishman, E.K.; Gerstenblith, G.; Moore, R.; Brinker, J.A.; Keruly, J.C.; Chen, S.; Detrick, B.; Lai, S. Vitamin D deficiency is associated with development of subclinical coronary artery disease in HIV-infected African American cocaine users with low Framingham-defined cardiovascular risk. Vasc. Health Risk Manag. 2013, 9, 729–737. [Google Scholar] [CrossRef] [Green Version]
- Teles, F.R.; Teles, R.P.; Martin, L.; Socransky, S.S.; Haffajee, A.D. Relationships Among Interleukin-6, Tumor Necrosis Factor-α, Adipokines, Vitamin D, and Chronic Periodontitis. J. Periodontol. 2012, 83, 1183–1191. [Google Scholar] [CrossRef] [PubMed]
- Zhan, Y.; Samietz, S.; Holtfreter, B.; Hannemann, A.; Meisel, P.; Nauck, M.; Völzke, H.; Wallaschofski, H.; Dietrich, T.; Kocher, T. Prospective Study of Serum 25-hydroxy Vitamin D and Tooth Loss. J. Dent. Res. 2014, 93, 639–644. [Google Scholar] [CrossRef] [PubMed]
- Garcia, M.N.; Hildebolt, C.F.; Miley, D.D.; Dixon, D.A.; Couture, R.A.; Spearie, C.L.A.; Langenwalter, E.M.; Shannon, W.D.; Deych, E.; Mueller, C.; et al. One-Year Effects of Vitamin D and Calcium Supplementation on Chronic Periodontitis. J. Periodontol. 2011, 82, 25–32. [Google Scholar] [CrossRef] [PubMed]
- Miley, D.D.; Garcia, M.N.; Hildebolt, C.F.; Shannon, W.D.; Couture, R.A.; Spearie, C.L.A.; Dixon, D.A.; Langenwalter, E.M.; Mueller, C.; Civitelli, R. Cross-Sectional Study of Vitamin D and Calcium Supplementation Effects on Chronic Periodontitis. J. Periodontol. 2009, 80, 1433–1439. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Humphrey, L.L.; Fu, R.; Buckley, D.I.; Freeman, M.; Helfand, M. Periodontal Disease and Coronary Heart Disease Incidence: A Systematic Review and Meta-analysis. J. Gen. Intern. Med. 2008, 23, 2079–2086. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amaliya, A.; Laine, M.L.; Delanghe, J.R.; Loos, B.G.; Van Wijk, A.J.; Van Der Velden, U. Java project on periodontal diseases: Periodontal bone loss in relation to environmental and systemic conditions. J. Clin. Periodontol. 2015, 42, 325–332. [Google Scholar] [CrossRef]
- Pink, C.; Kocher, T.D.; Meisel, P.; Dörr, M.; Markus, M.R.P.; Jablonowski, L.; Grotevendt, A.; Nauck, M.; Holtfreter, B. Longitudinal effects of systemic inflammation markers on periodontitis. J. Clin. Periodontol. 2015, 42, 988–997. [Google Scholar] [CrossRef] [PubMed]
- Polizzi, A.; Santonocito, S.; Vaccaro, M.; Fichera, G.; Torrisi, S.; Ronsivalle, V.; Palazzo, G.; Sicari, F.; Indelicato, F. Relationship between periodontitis and psychosocial impact in patients with systemic sclerosis: A clinical study. Mediterr. J. Clin. Psychol. 2020, 8, 2. [Google Scholar] [CrossRef]
- Bilgin Çetin, M.; Önder, C.; Orhan, K.; Kumbasar, D.; Serdar, M.A.; Ünsal, E. Relationship of periodontitis and edentulism to angiographically diagnosed coronary artery disease: A cross-sectional study. J. Periodontal Res. 2020, 55, 895–904. [Google Scholar] [CrossRef]
- Desai, C.S.; Lee, D.C.; Shah, S.J. Systemic sclerosis and the heart: Current diagnosis and management. Curr. Opin. Rheumatol. 2011, 23, 545–554. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Clinical Features | Controls (n = 37) | SSc (n = 35) | PT (n = 36) | SSc + PT (n= 36) | p-Value |
---|---|---|---|---|---|
Male, n (%) | 18 (42.8) | 16 (38) | 18 (39.4) | 15 (39.4) | 0.131 |
Age, mean ± SD | 52.9 ± 3.2 | 53.2 ± 3.5 | 52.7 ± 2.8 | 52.5 ± 2.9 | 0.057 |
Education level | |||||
Primary school, n (%) | 12 (28.6) | 13 (31) | 16 (34.9) | 14 (34.1) | 0.589 |
High school, n (%) | 15 (35.7) | 14 (33.3) | 11 (30.2) | 12 (34.1) | 0.563 |
College/university, n (%) | 10 (35.7) | 9 (35.7) | 9 (34.9) | 10 (31.7) | 0.558 |
Ethnicity | |||||
White, n (%) | 37 (100) | 35 (100) | 36 (100) | 36 (100) | 0.999 |
BMI, kg/m2, mean± SD | 24.2 ± 3.3 | 23.7 ± 3.2 | 24 ± 2.6 | 23.8 ± 3.1 | 0.081 |
Glucose, mg/dL, median (1st; 3rd) | 102.1 (85.9–105) | 105.1 (91–105.6) | 106.3 (98–102.3) | 107.1 (99–110.3) | 0.061 |
Uric acid, mg/dL, median (1st; 3rd) | 2.2 (1.8–2.9) | 3.3 (2.7–3.9) | 4.2 (3.2–4.6) | 4.6 (3.5–5.2) | <0.001 |
Albumin, g/L, median (1st; 3rd) | 37.1 (29.7–39.4) | 38.9 (35.5–40.6) | 39.9 (36.1–43.9) | 40.2 (35.8–44.1) | 0.258 |
Fibrinogen, mg/dL, median, (1st; 3rd) | 294.3 (259–310.3) | 299.2 (262.3–306) | 294.9 (284.9–318) | 311 (284.9–322.3) | 0.496 |
Apolipoprotein A, mg/dL, median (1st; 3rd) | 136.8 (112–154.1) | 138.9 (115–145.1) | 132 (119–141.3) | 138.6 (122–159) | 0.358 |
Total cholesterol, mg/dL, median (1st; 3rd) | 179.2 (169–187.2) | 185.1 (177–189) | 195.8 (181–202.3) | 191.9 (184–196) | 0.758 |
HDL-cholesterol, mg/dL, median (1st; 3rd) | 52.3 (45–56.3) | 53.9 (48.1–58.4) | 56.8 (52.2–60) | 57.1 (45–54) | 0.661 |
LDL-Cholesterol mg/dL, median (1st; 3rd) | 117.8 (98–121.3) | 122.1 (117–128) | 127 (116.3–131) | 123.4 (119–129) | 0.547 |
BUN, mg/dL, median (1st; 3rd) | 29.6 (25.1–33.2) | 31.5 (28.4–32.4) | 31.8 (28.9–33) | 33.1 (28–35.1) | 0.496 |
CRP, mg/dL, median (1st; 3rd) | 0.31 (0.25–0.34) | 0.4 (0.31–0.47) | 0.58 (0.41–0.65) | 0.59 (0.39–0.67) | <0.001 |
Systolic pressure, mm/hg, median (1st; 3rd) | 118 (115–123.1) | 123.6 (112–129) | 128.7 (119–142) | 125.6 (121–132) | <0.001 |
Diastolic pressure, mm/hg, median (1st; 3rd) | 86.3 (79.9–88.6) | 82.5 (80–88.7) | 85.5 (81.9–95) | 84.6 (82.6–87) | 0.024 |
Ferritin, ng/mL, median (1st; 3rd) | 80.3 (77.1–85.2) | 89.9 (84.2–92) | 95.7 (92–99.2) | 95.9 (91–97.5) | 0.059 |
Smoker, n (%) | 6 (19) | 5 (21.4) | 6 (21) | 7 (24.4) | 0.412 |
Current, n (%) | 7 (16.6) | 5 (14.3) | 4 (16.3) | 5 (19.5) | 0.636 |
Never, n (%) | 30 (81) | 30 (78.6) | 30 (79) | 29 (75.6) | 0.501 |
Past, n (%) | 1 (2.3) | - | 2 (4.6) | 2 (4.9) | 0.698 |
Comorbidities | |||||
Diabetes, n (%) | - | 3 (7.1) | 4 (14) | 4 (9.7) | <0.001 |
Atrial fibrillation, n (%) | - | 2 (4.7) | 2 (16.3) | 3 (7.3) | <0.001 |
Angina pectoris, n (%) | - | 3 (7.1) | 3 (39.5) | 4 (9.7) | <0.001 |
Stroke, n (%) | - | - | 3 (27.9) | 2 (2.4) | <0.001 |
Heart failure, n (%) | - | 1 (2.3) | 2 (23.5) | 1 (2.4) | <0.001 |
Drug treatment of CVD | |||||
Antihypertensive, n (%) | - | 4 (9.5) | 3 (32.5) | 6 (14.6) | <0.001 |
Statins, n (%) | - | 3 (7.1) | 5 (25.6) | 4 (9.7) | <0.001 |
Low-dose aspirin, n (%) | - | 2 (4.7) | 3 (30.2) | 2 (9.7) | <0.001 |
Beta-blockers, n (%) | - | 3 (7.1) | 2 (23.5) | 3 (12.2) | <0.001 |
SSc type, n (%) | |||||
Diffuse cutaneous SSc, n (%) | - | 32 (76.2) | - | 30 (73.2) | |
Limited cutaneous SSc, n (%) | - | 5 (11.9) | - | 6 (14.6) | |
Overlap syndrome, n (%) | - | 2 (4.7) | - | 3 (7.3) | |
Sclerosis sine scleroderma, n (%) | - | 2 (4.7) | - | 1 (2.4) | |
Undifferentiated SSc, n (%) | - | 1 (2.3) | - | 1 (2.4) | |
Disease duration | |||||
≤5years, n (%) | - | 19 (45.2) | - | 20 (48.9) | |
>5 to 10 years, n (%) | - | 12 (28.6) | - | 11 (26.8) | |
≥10 years, n (%) | - | 11 (26.2) | - | 10 (24.4) | |
Total SSc disease duration, median (1st; 3rd) | - | 7.3 (5.9–7.9) | - | 7.6 (5.8–8.2) | |
MRSS, Total score | 17.5 (16.4–18.3) | 18.9 (15.6–20.4) | |||
Vitamin D | |||||
Serum vitamin D, ng/mL, median (1st; 3rd) | 30.5 (28.8–32.3) | 21.1 (15.4–22.9) | 19.1 (17.6–26.8) | 15.9 (14.7–16.9) | <0.001 |
Dietary vitamin D intake (IU/Day), median (1st; 3rd) | 207.4 (199.9–212) | 202.6 (189–210.5) | 200.1 (181.6–215) | 199.1 (178.5–211) | 0.152 |
Supplementary vitamin D intake (IU/Day), median (1st; 3rd) | 246 (241.3–259) | 239.9 (231.4–256) | 235.4 (231–245) | 248.5 (241–259.2) | 0.812 |
Total vitamin D intake (IU/Day), median (1st; 3rd) | 446.9 (440.1–452) | 441.5 (429–451) | 439.6 (429.5–446) | 447.3 (412.3–458) | 0.654 |
Periodontal Parameters | |||||
Number of teeth, n, median (1st; 3rd) | 25.9 (22–26) | 22.6 (19–24) | 18.3 (18–23) | 17.9 (16–19) | <0.001 |
CAL, mm, median (1st; 3rd) | 1.4 (1.1–1.8) | 2.78 (2.1–3) | 4.28 (2–2.9) | 4.59 (3.1–5) | <0.001 |
Sites with CAL 4–5 mm (%) median (1st; 3rd) | - | - | 11.7 (9.9–15.8) | 35.7 (30.2–41.1) | <0.001 |
Sites with CAL ≥ 6 mm (%), median (1st; 3rd) | - | - | 14.4 (1.9–18.8) | 18.3 (15.9–25) | <0.001 |
PD, mm, median (1st; 3rd) | 1.48 (1.31–1.6) | 2.91 (2.6–3.5) | 4.41 (2.68–3.21) | 4.88 (4.12–5.2) | <0.001 |
Sites with PD 4–5 mm (%), median (1st; 3rd) | - | - | 44.3 (2.1–5.1) | 48.9 (40.2–53) | <0.001 |
Sites with PD ≥ 6 mm (%), median (1st; 3rd) | - | - | 21.3 (11.8–33.6) | 23.6 (17.8–29) | <0.001 |
BOP, median % (1st; 3rd) | 9.1 (8.5–9.1) | 11.8 (8.9–29) | 36.6 (10.6–18.6) | 41.1 (38.1–44.5) | <0.001 |
Plaque Index, median (1st; 3rd) | 0.82 (0.71–0.9) | 0.81 (0.71–0.9) | 1.02 (0.78–1.89) | 1.11 (0.71–0.95) | 0.097 |
Clinical Variables | CNT vs. SSc | CNT vs. PT | CNT vs. SSc + PT | SSc vs. PT | SSc vs. SSc + PT | PT vs. SSc + PT |
---|---|---|---|---|---|---|
Age | 0.899 | 0.071 | 0.658 | 0.124 | 0.313 | 0.312 |
BMI, kg/m2 | 0.165 | 0.312 | 0.133 | 0.289 | 0.229 | 0.201 |
Glucose, mg/dL | 0.923 | 0.589 | 0.158 | 0.587 | 0.587 | 0.209 |
Uric acid, mg/dL | 0.002 | 0.002 | 0.002 | 0.079 | 0.078 | 0.454 |
Albumin, g/L | 0.289 | 0.312 | 0.089 | 0.874 | 0.769 | 0.339 |
Fibrinogen, mg/dL | 0.451 | 0.287 | 0.366 | 0.329 | 0.323 | 0.551 |
Apolipoprotein A, mg/dL | 0.555 | 0.877 | 0.387 | 0.327 | 0.542 | 0.178 |
Total Cholesterol, mg/dL | 0.489 | 0.598 | 0.358 | 0.331 | 0.312 | 0.694 |
Triglycerides, mg/dL | 0.323 | 0.311 | 0.441 | 0.239 | 0.341 | 0.311 |
BUN, mg/dL | 0.554 | 0.462 | 0.439 | 0.698 | 0.491 | 0.369 |
CRP, mg/dL | <0.001 | <0.001 | <0.001 | 0.641 | 0.555 | 0.002 |
Systolic pressure, mm/Hg | 0.478 | <0.001 | <0.001 | <0.001 | <0.001 | 0.374 |
Diastolic pressure, mm/Hg | 0.605 | <0.001 | 0.004 | <0.001 | <0.001 | 0.321 |
Ferritin, mcg/L | 0.709 | 0.443 | 0.399 | 0.444 | 0.532 | 0.557 |
Serum Vitamin D, ng/mL | <0.001 | <0.001 | <0.001 | 0.021 | 0.019 | 0.009 |
Dietary Vitamin D intake (IU/Day) | 0.741 | 0.784 | 0.789 | 0.874 | 0.789 | 0.447 |
Supplementary Vitamin D intake (IU/Day) | 0.753 | 0.589 | 0.448 | 0.811 | 0.531 | 0.589 |
Total Vitamin D intake (IU/Day) | 0.589 | 0.854 | 0.599 | 0.423 | 0.339 | 0.872 |
Periodontal Parameters | ||||||
Number of teeth, n | <0.001 | <0.001 | <0.001 | <0.001 | 0.487 | <0.001 |
CAL, mm | <0.001 | <0.001 | <0.001 | <0.001 | 0.565 | <0.001 |
% of sites with CAL 4–5 mm | <0.001 | <0.001 | <0.001 | <0.001 | 0.445 | <0.001 |
% of sites with CAL ≥ 6 mm | <0.001 | <0.001 | <0.001 | <0.001 | 0.333 | <0.001 |
PD, mm | <0.001 | <0.001 | <0.001 | <0.001 | 0.589 | <0.001 |
% of sites with PD 4–5 mm | <0.001 | <0.001 | <0.001 | <0.001 | 0.611 | <0.001 |
% of sites with PD ≥ 6 mm | <0.001 | <0.001 | <0.001 | <0.001 | 0.331 | <0.001 |
BOP, % | <0.001 | <0.001 | <0.001 | <0.001 | 0.339 | <0.001 |
Plaque Index | 0.129 | 0.223 | 0.151 | 0.213 | 0.154 | 0.299 |
Variable | Number of Teeth | CAL | ||||
---|---|---|---|---|---|---|
Coefficient | 95% CI | p-Value | Coefficient | 95% CI | p-Value | |
Age | −0.13 | −0.21; −0.03 | 0.021 | 0.07 | 0.01; 0.55 | 0.043 |
Sex | 1.62 | 0.59; 2.29 | 0.007 | - | - | n.s. |
Serum vitamin D | 0.29 | 0.17; 0.41 | <0.001 | −0.15 | −0.21; −0.55 | <0.001 |
Dietary vitamin D | −0.19 | −0.32; 0.22 | 0.83 | - | - | n.s. |
CRP | −2.66 | −3.35; −1.79 | <0.001 | −0.39 | 0.24; 0.63 | <0.001 |
LDL Cholesterol | - | - | n.s. | 0.65 | 0.01; 0.79 | 0.089 |
Variable | PD | BOP | ||||
Coefficient | 95%C.I. | p-value | Coeffficient | 95%C.I. | p-value | |
Age | 0.05 | −0.03; 0.88 | 0.058 | 0.72 | 0.14; 1.46 | 0.008 |
Serum vitamin D | −0.15 | −0.13; −0.78 | <0.001 | −1.77 | −2.27; −1.31 | <0.001 |
CRP | −0.37 | −0.21; 0.54 | <0.001 | −4.21 | −3.38; 9.26 | <0.001 |
LDL Cholesterol | −0.17 | −0.01; 0.23 | 0.085 | - | - | n.s. |
Variable | Univariate Model | Multivariate Model | ||||
---|---|---|---|---|---|---|
B | 95% CI | p | B | 95% CI | p | |
Age (years) | −0.118 | −0.036;0.214 | 0.331 | −0.315 | −0.469; 0.113 | 0.314 |
Sex | 0.211 | −0.054;0.329 | 0.108 | 0.218 | −0.365; 0.178 | 0.087 |
Education | −0.096 | −0.108;0.364 | 0.067 | −0.103 | −0.196; 0.102 | 0.745 |
Smoking | −0.369 | −0.412;0.521 | 0.105 | −0.252 | −0.308;0.412 | 0.258 |
Triglycerides | −0.210 | −0.259;0.654 | 0.369 | −0.087 | −0.095;0.396 | 0.265 |
LDL Cholesterol | −0.395 | 0.409;0.458 | 0.021 | −0.354 | −0.419;0.415 | 0.089 |
HDL Cholesterol | 0.289 | 0.054;0.487 | 0.094 | 0.258 | −0.114;0.412 | 0.109 |
BMI | −0.275 | −0.301;0.331 | 0.328 | −0.119 | −0.174;0.258 | 0.156 |
PT | −0.356 | −0.386;0.588 | <0.001 | −0.389 | −0.159;0.661 | 0.011 |
SSc | −0.235 | −0.326; 0.317 | 0.359 | −0.208 | −0.352;0.247 | 0.257 |
CRP | −0.202 | −0.229;0.701 | 0.014 | −0.447 | −0.056;0.578 | 0.031 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Isola, G.; Palazzo, G.; Polizzi, A.; Murabito, P.; Giuffrida, C.; Lo Gullo, A. Association of Systemic Sclerosis and Periodontitis with Vitamin D Levels. Nutrients 2021, 13, 705. https://doi.org/10.3390/nu13020705
Isola G, Palazzo G, Polizzi A, Murabito P, Giuffrida C, Lo Gullo A. Association of Systemic Sclerosis and Periodontitis with Vitamin D Levels. Nutrients. 2021; 13(2):705. https://doi.org/10.3390/nu13020705
Chicago/Turabian StyleIsola, Gaetano, Giuseppe Palazzo, Alessandro Polizzi, Paolo Murabito, Clemente Giuffrida, and Alberto Lo Gullo. 2021. "Association of Systemic Sclerosis and Periodontitis with Vitamin D Levels" Nutrients 13, no. 2: 705. https://doi.org/10.3390/nu13020705
APA StyleIsola, G., Palazzo, G., Polizzi, A., Murabito, P., Giuffrida, C., & Lo Gullo, A. (2021). Association of Systemic Sclerosis and Periodontitis with Vitamin D Levels. Nutrients, 13(2), 705. https://doi.org/10.3390/nu13020705